 protein C concentrate (human) |
| Ceprotin |
Pharmaceutical
company:
Baxter Healthcare Corporation
www.baxter.com |
Pharmacologic classification: blood product
Therapeutic classification: anticoagulant
Pregnancy risk category: C
AVAILABLE FORMS
Single-dose vials: 500 international units/vial; 1,000 international units/vial
INDICATIONS AND DOSAGES
Acute episodes or short-term prevention of venous thrombosis and purpura fulminans in patients with severe congenital protein C deficiency--
Adults and children: Initially, 100 to 120 international units/kg by I.V.; followed by 60 to 80 international units/kg I.V. every 6 hours for three doses. Maintenance dose, 45 to 60 international units/kg I.V. every 6 or 12 hours.
Long-term prevention of venous thrombosis and purpura fulminans in patients with severe congenital protein C deficiency--
Adults and children: 45 to 60 international units/kg I.V. every 12 hours.
CONTRAINDICATIONS AND CAUTIONS
No known contraindications.
Use cautiously in patients requiring a low-sodium diet and in those with renal impairment; drug contains more than 200 mg of sodium.
Use cautiously in patients receiving tissue plasminogen activator or anticoagulants; may increase the risk for bleeding.
Drug contains heparin. Check platelet count and discontinue drug if heparin-induced thrombocytopenia is suspected.
INTERACTIONS
Drug-drug.
Tissue plasminogen activator, anticoagulants: May increase the risk of bleeding; monitor patient closely.
Vitamin K antagonists: May cause brief hypercoagulable state before desired anticoagulant effect.
ADVERSE REACTIONS
CNS: lightheadedness, restlessness, fever.
CV: hypotension.
Respiratory: hemothorax.
Other: hypersensitivity or allergic reactions (itching and rash), hyperhydrosis.
Reactions may be common, uncommon, life-threatening,
or COMMON AND LIFE-THREATENING.
|
